NOS2 enhances KRAS‐induced lung carcinogenesis, inflammation and microRNA‐21 expression
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Mutant KRAS in lung cancers induces molecular pathways that regulate cellular proliferation, survival and inflammation, which enhance tumorigenesis. Inducible nitric oxide synthase (NOS2) upregulation and sustained nitric oxide generation are induced during the inflammatory response and correlate positively with lung tumorigenesis. To explore the mechanistic contribution of NOS2 to KRAS‐induced lung tumorigenesis and inflammation, we used a genetic strategy of crossing NOS2 knockout (NOS2KO) C57BL6 inbred mice with a KRASG12D‐driven mouse lung cancer model. KRAS G12D;NOS2KO mice exhibited delayed lung tumorigenesis and a longer overall survival time compared to that of KRAS G12D;NOS2WT (wild‐type) controls. Correspondingly, tumors in KRAS G12D;NOS2KO mice had reduced tumor cell proliferation in adenomas and carcinomas. NOS2 deficiency also led to markedly suppressed inflammatory response by attenuation of macrophage recruitment into alveoli and within tumor foci. In contrast, FOXP3+ regulatory T cells were increased in tumors from KRAS G12D;NOS2KO mice. We further analyzed the expression of microRNA‐21 (miR‐21), an oncogenic noncoding RNA involved in oncogenic Ras signaling, by quantitative reverse‐transcription polymerase chain reaction and in situ hybridization. Lung carcinomas dissected from KRAS G12D;NOS2KO mice showed a significantly reduced miR‐21 expression along with decreased tumor cell proliferation, suggesting that NOS2 deficiency could attenuate RAS signaling pathways that transactivate miR‐21 expression. Therefore, deletion of NOS2 decreases lung tumor growth as well as inflammatory responses initiated by oncogenic KRAS, suggesting that both KRAS and NOS2 cooperate in driving lung tumorigenesis and inflammation. Inhibition of NOS2 may have a therapeutic value in lung cancers with oncogenic KRAS mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The widespread regulation of microRNA biogenesis, function and decay
Krol, J., Loedige, I., & Filipowicz, W. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2843 · Cited by 4,672
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis
Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R. M., Okamoto, A., Yokota, J., Tanaka, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.01.025 · Cited by 3,023 · cited 3×
“Accordingly, KRAS mutations represent a biologically and clinically relevant molecular subset in patients with NSCLC.”
BackgroundSelf-citationModulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21
Hatley, M. E., Patrick, D. M., Garcia, M. R., Richardson, J. A., Bassel-Duby, R., van Rooij, E., & Olson, E. N. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.013 · Cited by 626 · cited 1×
“demonstrated an in vivo autoregulatory loop between oncogenic Ras and miR21 by using gain-of-function transgenic mice and loss-offunction KO mice of miR-21 allele in combination with the KRAS lung cancer mouse model.(17) The authors showed that Ras activation increases the expression of miR-21, and in turn, miR-21 enh…”
MethodMiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers
Seike, M., Goto, A., Okano, T., Bowman, E. D., Schetter, A. J., Horikawa, I., Mathe, E. A., Jen, J., Yang, P., Sugimura, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905234106 · Cited by 500
Self-citationOncogenic Ras-induced secretion of IL6 is required for tumorigenesis
Ancrile, B., Lim, K.-H., & Counter, C. M. (2007) · Genes & Development · doi:10.1101/gad.1549407 · Cited by 422
Yang, G., Rosen, D. G., Zhang, Z., Bast, R. C., Mills, G. B., Colacino, J. A., Mercado-Uribe, I., & Liu, J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605752103 · Cited by 341 · cited 2×
“KRAS induces immune responses by upregulating the production of chemokines and cytokines, which are key transcriptional targets of Ras and are required for Ras-driven tumorigenesis.(4,6,45) Consistent with previously reported lung cancer mouse models of KRAS, we observed an abundant accumulation of neutrophils and mac…”
Backgroundp53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence
Fujita, K., Mondal, A. M., Horikawa, I., Nguyen, G. H., Kumamoto, K., Sohn, J. J., Bowman, E. D., Mathe, E. A., Schetter, A. J., Pine, S. R., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1928 · Cited by 336
Self-citationClassification of Proliferative Pulmonary Lesions of the Mouse
Nikitin, A. Y., Alcaraz, A., Anver, M. R., Bronson, R. T., Cardiff, R. D., Dixon, D., Fraire, A. E., Gabrielson, E. W., Gunning, W. T., Haines, D. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3376 · Cited by 334 · cited 1×
“Tumors were categorized as hyperplasia, adenoma and carcinoma based on previously established criteria.(39) Severity of inflammation, ‘‘pneumonia, acidophilic macrophage’’ (PAM), was graded into one of five levels, according to the amount and degree of lung involvement.”
MethodKobayashi, Y. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0310149 · Cited by 306
Thomas, D. D., Espey, M. G., Ridnour, L. A., Hofseth, L. J., Mancardi, D., Harris, C. C., & Wink, D. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400453101 · Cited by 289
Self-citation
Cited by
Tumor Immunology and Tumor Evolution: Intertwined Histories
Galon, J., & Bruni, D. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.018 · Cited by 540
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer
Topper, M. J., Vaz, M., Chiappinelli, K. B., DeStefano Shields, C. E., Niknafs, N., Yen, R.-W. C., Wenzel, A., Hicks, J., Ballew, M., Stone, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.022 · Cited by 537
“First, there was a robust alteration in the distribution of F4/80 macrophages, which have been shown to have an established role in the progression of the LSL-Kras mouse model (Okayama et al., 2013).”
The yin and yang of nitric oxide in cancer progression
Burke, A. J., Sullivan, F. J., Giles, F. J., & Glynn, S. A. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt034 · Cited by 370
Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression
Heinecke, J. L., Ridnour, L. A., Cheng, R. Y. S., Switzer, C. H., Lizardo, M. M., Khanna, C., Glynn, S. A., Hussain, S. P., Young, H. A., Ambs, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401799111 · Cited by 177
Self-citationProteomic analysis of the NOS2 interactome in human airway epithelial cells
Foster, M. W., Thompson, J. W., Forrester, M. T., Sha, Y., McMahon, T. J., Bowles, D. E., Moseley, M. A., & Marshall, H. E. (2013) · Nitric Oxide · doi:10.1016/j.niox.2013.02.079 · Cited by 25
Metadata
- Authors
- Okayama, H., Saito, M., Oue, N., Weiss, J. M., Stauffer, J., Takenoshita, S., Wiltrout, R. H., Hussain, S. P., & Harris, C. C.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2012-06-13
- Volume
- 132
- Issue
- 1
- Pages
- 9-18
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2036733146
- Cited by
- 75
- References
- 12
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NOS2 enhances KRAS‐induced lung carcinogenesis, inflammation and microRNA‐21 expression. https://app.cochat.ai/papers/10.1002/ijc.27644
- The paper
- Okayama, H., Saito, M., Oue, N., Weiss, J. M., Stauffer, J., Takenoshita, S., Wiltrout, R. H., Hussain, S. P., & Harris, C. C. (2013). NOS2 enhances KRAS‐induced lung carcinogenesis, inflammation and microRNA‐21 expression. International Journal of Cancer. https://doi.org/10.1002/ijc.27644
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.